Fig. 4.

Involvement of MAPK in the antidepressant-like effect of guanosine in the TST. Timeline of experimental protocols of administrations and behavioral tests (a, b). Effects of pretreatment of mice with U0126 on the anti-immobility effect of guanosine in TST (guanosine treatment: F_(1,24) = 3.86, p = 0.06; U0126 treatment: F_(1,24) = 16.83, p < 0.01; guanosine treatment × U0126 interaction: F_(1,24) = 13.37, p < 0.05) (c). Effects of pretreatment of mice with U0126 and guanosine on the locomotor activity in the OFT (guanosine treatment F_(1,24) = 0.41, p = 0.52; U0126 treatment F_(1,24) = 3.49, p = 0.07; guanosine × U0126 interaction F_(1,24) = 0.79, p = 0.38) (e). Effects of pretreatment of mice with PD98059 on the anti-immobility effect of guanosine in TST (guanosine treatment: F_(1,24) = 7.60, p < 0.05; PD98059 treatment: F_(1,24) = 8.22, p < 0.01; guanosine treatment × PD98059 interaction: F_(1,24) = 5.38, p < 0.05) (d). Effects of pretreatment of mice with PD98059 and guanosine on the locomotor activity in the OFT (guanosine treatment: F_(1,24) = 0.22, p = 0.64; PD98059 treatment F_(1,24) = 3.21, p = 0.09; guanosine × PD98059 interaction: F_(1,24) = 0.13, p = 0.71) (f). Values are expressed as mean + S.E.M. of 7 mice. **p < 0.01 compared with the vehicle-treated control group, ##p < 0.01 compared with the group treated with guanosine + vehicle